MA50082A - Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer - Google Patents

Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer

Info

Publication number
MA50082A
MA50082A MA050082A MA50082A MA50082A MA 50082 A MA50082 A MA 50082A MA 050082 A MA050082 A MA 050082A MA 50082 A MA50082 A MA 50082A MA 50082 A MA50082 A MA 50082A
Authority
MA
Morocco
Prior art keywords
cancer treatment
enpp1 inhibitors
enpp1
inhibitors
cancer
Prior art date
Application number
MA050082A
Other languages
English (en)
Inventor
Volker Boehnert
Jacqueline Ann Carozza
Lingyin Li
Kelsey Erin Shaw
Mark Smith
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MA50082A publication Critical patent/MA50082A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050082A 2017-09-08 2018-09-07 Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer MA50082A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762556117P 2017-09-08 2017-09-08

Publications (1)

Publication Number Publication Date
MA50082A true MA50082A (fr) 2020-07-15

Family

ID=63714052

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050082A MA50082A (fr) 2017-09-08 2018-09-07 Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer

Country Status (18)

Country Link
US (3) US11701371B2 (fr)
EP (2) EP3678668B1 (fr)
JP (2) JP7292740B2 (fr)
KR (2) KR20240151869A (fr)
CN (2) CN111372587B (fr)
AU (3) AU2018330188C1 (fr)
BR (1) BR112020004559A2 (fr)
CA (1) CA3074268A1 (fr)
DK (1) DK3678668T3 (fr)
EA (1) EA202090595A1 (fr)
ES (1) ES2975183T3 (fr)
HU (1) HUE066413T2 (fr)
IL (3) IL272948B2 (fr)
MA (1) MA50082A (fr)
MX (2) MX2020002646A (fr)
PL (1) PL3678668T3 (fr)
SG (1) SG11202001728YA (fr)
WO (1) WO2019051269A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220056052A1 (en) * 2018-12-28 2022-02-24 Riboscience Llc Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
CA3151277A1 (fr) 2019-09-16 2021-03-25 Aten Porus Lifesciences Pvt. Ltd. Composes de thiopurine 2-amino-s6-substitues en tant qu'inhibiteurs de la proteine enpp1
WO2021061803A1 (fr) * 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Inhibiteurs de phosphodiestérase et leur utilisation
EP4100394B1 (fr) * 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibiteurs de l'ectonucléotide pyrophosphatase/phosphodiestérase 1 (enpp1) et leurs procédés d'utilisation
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2021203772A1 (fr) * 2020-04-09 2021-10-14 Betta Pharmaceuticals Co., Ltd Inhibiteurs d'ectonucléotide pyrophosphatase-phosphodiestérase 1, compositions et utilisations de ceux-ci
WO2021225969A1 (fr) * 2020-05-04 2021-11-11 Volastra Therapeutics, Inc. Inhibiteurs imino sulfanone de l'enpp1
US11834512B2 (en) * 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
KR102682428B1 (ko) 2020-05-08 2024-07-05 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
US20230159469A1 (en) 2020-05-08 2023-05-25 Txinno Bioscience Inc. Novel phthalazine derivative having ectonucloeotide pyrophosphatase/phosphodieste rase inhibitory activity, and use thereof
TW202214640A (zh) 2020-06-16 2022-04-16 美商佛拉斯托醫療公司 Ｅｎｐｐ１之雜環抑制劑
US11873291B2 (en) * 2020-09-03 2024-01-16 Immunesensor Therapeutics, Inc. Quinoline cGAS antagonist compounds
WO2022091048A1 (fr) 2020-10-30 2022-05-05 Integral Biosciences Private Limited Inhibiteurs d'ectonucléotide pyrophosphatase-phosphodiestérase 1 (enpp1) et leurs utilisations
CN116600813A (zh) * 2020-12-09 2023-08-15 斯汀格瑞治疗股份有限公司 作为enpp1和cdnp抑制剂的膦酸盐
WO2022125613A1 (fr) * 2020-12-09 2022-06-16 Stingray Therapeutics, Inc. Phosphonates en tant qu'inhibiteurs d'enpp1 et cdnp
AU2021412688B2 (en) 2020-12-29 2025-06-12 Txinno Bioscience Inc. Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof
KR102720206B1 (ko) 2020-12-29 2024-10-21 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
KR102686866B1 (ko) 2021-01-29 2024-07-19 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
CA3204409C (fr) 2021-01-29 2026-04-28 Txinno Bioscience Inc. Dérivé de benzotriazole présentant une activité inhibitrice contre l’ectonucléotide pyrophosphatase-phosphodiestérase et son utilisation
WO2022197734A1 (fr) * 2021-03-16 2022-09-22 Riboscience Llc Dérivés de boronate hétéroaryle bicycliques utilisés comme inhibiteurs de l'ecto-nucléotide pyrophosphatase/phosphodiestérase 1
WO2022212488A1 (fr) * 2021-03-31 2022-10-06 Riboscience Llc Dérivés bicycliques d'hétéroaryle phosphonate en tant qu'inhibiteurs d'éctonucléotide pyrophosphatase/phosphodiestérase 1
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN115536696B (zh) * 2021-06-29 2023-07-14 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
CA3228162A1 (fr) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Composes phospholipidiques et leurs procedes de production et d'utilisation
EP4395786A4 (fr) * 2021-09-03 2025-07-23 Angarus Therapeutics Inc Inhibiteurs d'enpp1 et cellules immunitaires exprimant des récepteurs d'antigènes chimériques
WO2023077083A1 (fr) * 2021-10-29 2023-05-04 Angarus Therapeutics, Inc. Inhibiteurs d'enpp1 en tant qu'inhibiteurs de métastases
EP4486734A1 (fr) 2022-03-02 2025-01-08 Immunesensor Therapeutics, Inc. Composés de quinoléine antagonistes de cgas
CN118488950A (zh) * 2022-04-11 2024-08-13 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
EP4514331A1 (fr) 2022-04-29 2025-03-05 Petragen, Inc. Inhibiteurs de l'enpp1 et modulation de la croissance osseuse
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
WO2024028727A1 (fr) * 2022-08-01 2024-02-08 Sravathi Ai Technology Private Limited Nouveaux inhibiteurs d'ectonucléotide pyrophosphatase/phosphodiestérase 1 (enpp-1) et leurs utilisations
WO2024213932A1 (fr) * 2023-04-11 2024-10-17 The Hong Kong University Of Science And Technology Commande de régénération d'axones par de nouveaux inhibiteurs d'enpp1
WO2024216211A2 (fr) * 2023-04-14 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Procédés d'inhibition de la progression d'une tumeur et de la métastase par inhibition de enpp1
CN118108720B (zh) * 2023-12-28 2026-03-10 河南大学 一种苝酰亚胺衍生物pdic-ns及应用
WO2025207514A1 (fr) * 2024-03-25 2025-10-02 Riboscience Llc Dérivés de sulfanediimine hétéroaryle bicycliques utilisés en tant qu'inhibiteurs de l'ectonucléotide pyrophosphatase phosphodiestérase 1

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA228044A (fr) 1923-01-16 Thomas Noble Boughton Matrice a faconner des boulons
CA190896A (fr) 1919-02-24 1919-06-17 Josephat C. Bergeron Dispositif de montre
DE3319795A1 (de) 1983-06-01 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von phosphonsaeureestern
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
EP0831100B1 (fr) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Nouveaux derives peptidiques
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2002072578A2 (fr) 2001-03-08 2002-09-19 Millennium Pharmaceuticals Composes de quinoline heterocycliques contenant de l'azote
US20040101840A1 (en) * 2001-04-27 2004-05-27 Chung Leland W.K. Identification, cloning and characterization of a novel pc-1 gene differentially expressed in prostate cells and tissues
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
UA83814C2 (ru) 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR101676062B1 (ko) * 2009-04-11 2016-11-14 어레이 바이오파마 인크. Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제
ES2624845T3 (es) 2010-09-29 2017-07-17 Intervet International B.V. Compuestos de N-heteroarilo con unidad de puente cíclico para el tratamiento de enfermedades parasitarias
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
CA2962329C (fr) * 2014-09-22 2023-12-19 Yu-Sheng Chao Composes heterocycliques et utilisation de ces composes
US10011600B2 (en) * 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EP3233089A4 (fr) * 2014-12-17 2018-11-14 Lipogen LLC Procédé de traitement du cancer avec cgamp ou cgasmp
CN105153153A (zh) 2015-08-31 2015-12-16 吉林奥来德光电材料股份有限公司 一种新的芳香族胺类化合物及其制备与应用
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
CA3047579A1 (fr) 2016-12-22 2018-06-28 Abbvie Inc. Compositions et procedes d'amelioration ou d'augmentation de la production d'ifn de type i
CN110312424A (zh) 2017-01-09 2019-10-08 澳大利亚国立大学 用于改善杀虫剂的增效剂
US10518257B2 (en) 2017-05-04 2019-12-31 Exxonmobil Research And Engineering Company Metal organic frameworks, their synthesis and use
WO2018229139A1 (fr) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Nouveaux composés destinés à être utilisés pour le cancer
AU2018325445A1 (en) 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
MX2021009269A (es) 2019-02-01 2021-08-24 Univ Leland Stanford Junior Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Also Published As

Publication number Publication date
JP7607969B2 (ja) 2025-01-06
AU2024200148B2 (en) 2026-02-26
EP3678668A1 (fr) 2020-07-15
EP3678668B1 (fr) 2024-01-10
US20230103498A1 (en) 2023-04-06
US11701371B2 (en) 2023-07-18
DK3678668T3 (da) 2024-04-08
US20210369747A1 (en) 2021-12-02
CN111372587A (zh) 2020-07-03
IL272948A (en) 2020-04-30
KR20200066292A (ko) 2020-06-09
PL3678668T3 (pl) 2024-06-03
EP4327882A3 (fr) 2024-05-15
WO2019051269A1 (fr) 2019-03-14
AU2018330188B2 (en) 2023-10-19
IL302338A (en) 2023-06-01
AU2018330188C1 (en) 2024-02-29
EP4327882A2 (fr) 2024-02-28
BR112020004559A2 (pt) 2020-09-24
ES2975183T3 (es) 2024-07-03
CA3074268A1 (fr) 2019-03-14
AU2026200707A1 (en) 2026-02-19
AU2018330188A1 (en) 2020-04-23
IL302338B1 (en) 2024-06-01
IL311010A (en) 2024-04-01
RU2020112299A3 (fr) 2022-03-14
IL272948B2 (en) 2023-09-01
JP2023101715A (ja) 2023-07-21
MX2020002646A (es) 2020-09-25
US11707471B2 (en) 2023-07-25
JP7292740B2 (ja) 2023-06-19
AU2024200148A1 (en) 2024-01-25
IL302338B2 (en) 2024-10-01
SG11202001728YA (en) 2020-03-30
KR102715420B1 (ko) 2024-10-10
CN111372587B (zh) 2024-01-09
JP2020533288A (ja) 2020-11-19
RU2020112299A (ru) 2021-10-08
EA202090595A1 (ru) 2020-06-29
HUE066413T2 (hu) 2024-08-28
MX2023007193A (es) 2023-07-03
CN117883449A (zh) 2024-04-16
IL272948B1 (en) 2023-05-01
US20230277570A1 (en) 2023-09-07
KR20240151869A (ko) 2024-10-18

Similar Documents

Publication Publication Date Title
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3873205A4 (fr) Substances et méthodes pour le traitement du cancer